is used to maintain epidural analgesia following initial intrathecal analgesia. This trial investigated whether a continuous background infusion with PCEA provides superior analgesia to PCEA alone among patients who received combined spinal-epidural (CSE) analgesia during labour.
Combined spinal-epidural (CSE) analgesia for labour pain relief is an increasingly popular technique [1] [2] [3] [4] . CSE has several advantages over conventional epidural analgesia: rapid onset of analgesia with minimal motor block, reduced anaesthetic requirements, symmetrical spread of analgesia and increased patient satisfaction [1] [2] [3] [4] [5] . Following the initial spinal drug administration, analgesia is maintained using epidurally administered drugs, using a continuous epidural infusion (CEI), patient-controlled epidural analgesia (PCEA), a combination of both, or intermittent bolus epidural analgesia (IBEA) administered by midwives or anaesthetists. For maintenance of conventional labour epidural analgesia, PCEA offers several advantages over CEI [6] [7] [8] . Recent metaanalysis concluded that parturients who receive PCEA are less likely to require anaesthetist interventions for breakthrough pain, require lower doses of local anaesthetic and have less motor block 9 .
Experience with PCEA following initial intrathecal analgesia is limited. Collis and co-workers compared CEI, IBEA and PCEA and concluded that analgesia was similar in the three groups but that PCEA resulted in less motor block 10 . At our institution, PCEA, without a background epidural infusion, is used to maintain analgesia throughout labour as part of a CSE technique. We noted that significant numbers of parturients required interventions for pain, especially around the time the initial spinal dose wore off, when they found it difficult to re-establish adequate analgesia with PCEA alone.
Conflicting evidence exists as to the role of a background infusion added to PCEA following conventional labour epidural analgesia. Paech did not observe any analgesic benefit and did not notice a reduction of the need for epidural supplementation when a background infusion was added to the PCEA modality 11 . Boselli and colleagues also found no improvement in analgesia, but reported increased drug consumption with higher infusion rates 12 . Other studies however, suggested that adding a background infusion does improve analgesia and reduce staff workload 13, 14 . There are no studies that have investigated PCEA, with or without a background infusion, as part of CSE analgesia.
We postulated a background infusion might reduce the incidence of breakthrough pain once the spinal component has worn off. Therefore, we designed a double-blind, randomized trial comparing PCEA and PCEA+CEI, started immediately after initiation of spinal analgesia. We hypothesized that following CSE analgesia, PCEA+CEI would provide superior analgesia as compared with PCEA, without increasing local anaesthetic consumption. The primary outcome variables were the number of patients requiring an anaesthetist intervention for breakthrough pain and the hourly local anaesthetic consumption.
METHODS
Following institutional ethics approval and written patient informed consent, we recruited 80 healthy, term parturients to this double-blind, randomized clinical trial. Parturients were of mixed parity, in active labour, with singleton pregnancies and vertex presentation. Exclusion criteria were preterm labour (<36 weeks), known or suspected fetal abnormalities, breech presentation and maternal American Society of Anesthesiologists (ASA) physical status class III or IV.
Maternal age, height, weight, parity, pregnancy duration, cervical dilation, status of the membranes and type of labour were noted. Maternal blood pressure and maternal heart rate during the last antenatal visit and just before CSE placement were recorded. Fetal heart rate was recorded for 15 minutes prior to analgesia, using external cardiotocography. Pain was assessed using a visual analogue scale (0=no pain, 100=worst imaginable pain) 5 minutes prior to CSE.
Following intravenous (IV) hydration with 1000 ml of lactated Ringer's solution, a CSE technique was performed at the L3-L4 interspace with the patient in the sitting position. The epidural space was located using loss-of-resistance to saline with an 18 gauge Tuohy needle. Spinal puncture was performed using a 27 gauge pencil-point needle. Ropivacaine 3 mg and sufentanil 1.5 µg in 2 ml of saline was given intrathecally. A 20 gauge epidural catheter was inserted 5 cm into the epidural space and checked by aspiration. No test dose was given. The catheter was secured and the patient was positioned in left lateral decubitus position.
Immediately after initiation of analgesia, a PCEA device (Alaris Medical Systems, IVAC PCAM pump) filled with ropivacaine 1.5 mg/ml and sufentanil 0.75 µg/ml was activated. Patients were randomly assigned, by drawing sealed, opaque envelopes containing a computer generated number, into one of two groups. The PCEA group could receive a 4 ml bolus with a lockout period of 15 minutes, without continuous epidural infusion. In the PCEA+CEI group, in addition to the same variables, parturients received a continuous epidural infusion of the same epidural solution at 2 ml/h. Both the patient and the anaesthetist collecting the data were blinded to the group assignment by covering the PCEA device screen. If delivery occurred within 60 minutes from the initiation of analgesia, participants were excluded from further analysis.
Data (pain and satisfaction scores [0=very dissatisfied, 100=very satisfied], maternal blood pressure, maternal heart rate and the incidence of pruritus or nausea) were collected at regular time intervals during the first hour after placement of the CSE and thereafter every hour until delivery. Block height was assessed using a cold ether swab and motor block quantified using the Bromage score. The number of interventions for breakthrough pain made by the attending anaesthetist and the number of patients requiring interventions were noted. Breakthrough pain was defined as insufficient pain relief such that a maternal request for additional analgesia was made. Additional epidural boluses consisted of 10 ml of the same epidural solution. After childbirth, the total amount of anaesthetic used, the duration of labour and the mode of delivery were recorded. Neonatal evaluation consisted of Apgar scores, neonatal weight and umbilical artery blood gas analysis, and requirement for neonatal intensive care.
To determine the power of the study, the trial was conducted in two phases. Initially 50 patients were randomized, after which a planned interim analysis was performed by an anaesthetist not involved in the randomization process or data collection. This showed that breakthrough pain following initial spinal analgesia had occurred in 60% of patients in the PCEA group and in 24% of the patients in the PCEA+CEI group. Power analysis showed that to achieve 95% power for an anticipated reduction in the incidence of breakthrough pain from 60 to 20% in the PCEA and PCEA+CEI groups respectively, 36 patients in each group were required. The investigators were unaware of the results of the interim analysis and a further 30 patients were randomized. Continuous variables were statistically analysed using analysis of variance and Scheffé's post hoc test when appropriate. Categorical data were analysed using the Fisher's exact test and Chi-square analysis. A P value <0.05 was considered significant. Results are expressed as the mean±standard deviation (SD) or number within group, unless otherwise specified.
RESULTS
Eighty patients participated, with 40 in each group. Two patients in the PCEA group were excluded from analysis because delivery occurred within 60 minutes of initiation of spinal analgesia. There were no differences in demographic and obstetric data between the groups (Table 1) .
Analgesia, at predetermined time points throughout labour, was similar between the groups ( Figure  1 ). Significantly more patients in the PCEA group required at least one anaesthetist intervention for breakthrough pain (27 [71%] vs 10 [25%] in the PCEA+CEI group) ( Table 2 ) and more interventions were performed ( Table 2 ). Consumption of local anaesthetic (PCEA bolus and continuous infusion, not including manually administered boluses) was similar between the groups (Table 3) , with 6.7± 3.5 mg versus 7.0±3.4 mg of ropivacaine used per hour (PCEA and PCEA+CEI groups respectively). If anaesthetist-administered boluses were included, more local anaesthetic was consumed by the PCEA group (Table 3) . Block height was similar between the groups and no parturient had a level of sensory block above the T6 dermatome.
No differences in maternal side-effects were observed ( Table 2) . Maternal haemodynamic parameters remained stable throughout labour in both groups. The number of patients needing ephedrine and the total amount of ephedrine administered per patient was similar between the groups ( Table 2 ). There were no differences in obstetric outcome, or neonatal outcome, between the groups (Table 4) .
DISCUSSION
This randomized, double-blind trial demonstrated that adding a small (2 ml/h) continuous epidural infusion as a background to PCEA maintenance of epidural analgesia, following CSE analgesia, reduced the incidence of breakthrough pain and the number of anaesthetic interventions. It did not increase local anaesthetic consumption.
Conflicting evidence exists as to the role of a background infusion added to PCEA following conventional labour epidural analgesia [11] [12] [13] [14] [15] . Paech studied the issue first and concluded that the addition of a background infusion conferred no benefit in terms of quality of analgesia or local anaesthetic consumption 11 . Petry and colleagues and Boselli and colleagues reported similar observations but noted an increased local anaesthetic consumption when adding a background infusion 12, 15 . However, Ferrante and coworkers observed significantly less physician administered boluses when a background infusion was added to PCEA, without increasing local anaesthetic consumption 13 . These results were recently supported by those of Campbell and co-workers 14 . The results of the present study also support the latter two studies. We cannot provide a conclusive explanation for the observed differences between trials. However, differences in local anaesthetic solution, PCEA and background infusion settings and in obstetric practice might have contributed to the discrepancies.
How can we explain the clinically important impact of a very small continuous background infusion on the incidence of breakthrough pain? It is known that starting an epidural infusion immediately following the initiation of CSE analgesia significantly prolongs spinal analgesia 16 . Rawal and colleagues hypothesized that subarachnoid spread of epidurally administered drugs occurs through the duro-arachnoid hole 17 . High spinal anaesthesia following epidural anaesthesia after an accidental dural puncture has been reported 18, 19 . In vitro studies have demonstrated an increased flux of lignocaine and morphine through meningeal tissue after perforation by a spinal needle 20 . Swenson and co-workers found that morphine concentrations in the cerebrospinal fluid are increased, varying with the presence and the size of a dural hole 21 . Leighton and co-workers showed that a previous dural puncture increased the dermatomal spread of subsequently administered epidural local anaesthetic 22 .
Two further mechanisms might be involved. Carrie and co-workers introduced the concept of "subclinical analgesia" 23 , with sensory nerves affected to a subclinical degree. Administration of epidural anaesthetic might strengthen analgesia by transdural migration. Furthermore, cephalad shift of local anaesthetic within the cerebrospinal fluid occurs after epidural injection, caused by compression of the dural sac 24, 25 .
We chose to use a low rate of background infusion because PCEA supplemented by a high volume infusions (especially consisting of more than 50% of total hourly consumption) increases local anaesthetic consumption and possibly problematic motor block 12, 13 . Currently, we are evaluating whether increasing the infusion rate confers an advantage with respect to breakthrough pain. Other areas for further study include the optimal PCEA dose, lockout time and epidural solution.
As an alternative to using a background infusion, we could have increased the PCEA bolus size or reduced the lockout time, in an attempt to improve analgesic quality following initial spinal analgesia. We opted for PCEA settings that have proven effective after conventional epidural labour analgesia and we were concerned that by increasing the dose or reducing the lockout interval, local anaesthetic consumption might increase without reducing the need for additional supplementary doses.
Based on our results, we conclude that a continuous epidural infusion of ropivacaine 0.15% and sufentanil 0.75 µg/ml at 2 ml/h combined with PCEA (4 ml bolus of the same solution, with a lockout time of 15 minutes) provides labour analgesia with less anaesthetic workload for parturients receiving CSE analgesia. Currently, this approach for PCEA has become the standard in our labour and delivery suite. 
